APC
IRD

Aspire Private Capital’s Opus Genetics IRD Stock Holding History

Aspire Private Capital’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-400
Closed -$1.5K – 690
2023
Q1 		$1.5K Hold
400
– – ﹤0.01% 551
2022
Q4 		$1.41K Hold
400
– – ﹤0.01% 540
2022
Q3 		$1K Hold
400
– – ﹤0.01% 598
2022
Q2 		$1K Hold
400
– – ﹤0.01% 588
2022
Q1 		$1K Hold
400
– – ﹤0.01% 581
2021
Q4 		$1K Buy
+400
New +$1.6K ﹤0.01% 617

Other funds holding IRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

Aspire Private Capital's IRD Position: Q2 2023 in Review

Aspire Private Capital sold out of Opus Genetics (IRD) in Q2 2023, closing a stake of 400 shares — an estimated $1.5K sold.

Aspire Private Capital first reported a position in IRD in Q4 2021 and held it in 6 quarters. The position peaked at $1.5K in Q1 2023. 49 funds tracked by Wall St. Rank hold IRD as of Q2 2023.

  • Aspire Private Capital reported no remaining Opus Genetics position as of Q2 2023 after selling out during the quarter.
  • Aspire Private Capital sold 400 Opus Genetics shares in Q2 2023, an estimated $1.5K.
  • Aspire Private Capital first reported a position in Opus Genetics in Q4 2021 and held it in 6 quarters.
  • Aspire Private Capital's Opus Genetics position peaked at $1.5K in Q1 2023.
  • 49 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2023.

Based on Aspire Private Capital's 13F filing for Q2 2023, filed 24 Jul 2023.